Effect of Pharmacogenetic-Based Decision Support Tools in Improving Depression Outcomes: A Systematic Review.

At the end of the study period, the rate was higher in the PGX-guided group, but the difference did not reach statistical significance ( p =0.071). 29 The results of the RCT by Greden et al showed a statistically significant higher remission rate in the GeneSight-guided group (15.3%) compared to TAU (10.1%) ( p =0.007). 30 The remission rate in the RCT by Thase et al was 18.2% higher in the GeneSight-guided arm compared to 10.7% in TAU (∆=7.5%, p =0.003) in patients with previous antidepressant failures. 31 Safety Summary There was a general inconsistency and lack of data on safety outcomes in the included reviews.

also in 111,027 other papers

The systematic review by Fabbri et al showed that patients in the PGX group had a weak lower risk of medication tolerability problems, lower mean number of rehospitalizations, and borderline significant lower number of emergency room visits within 2-month follow-up based on RCT results. 25 A summary of these results as reported in the individual reviews is presented in Table 4 .

also in 11,409 other papers